Actualités

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Cooper Cos. could get a pop from the sale of a surgical unit. What two activists are up to in the stock.

A mix of high expectations, profit-taking, and a slight dip in valuations has sent S&P 500 stocks sputtering even after solid earnings reports.

The number that separates a comfortable retirement from a perpetual side hustle depends entirely on which yield tier you trust with your capital, and the answer surprises most income investors who assume bigger payouts always win.

Johnson and Johnson just committed over a billion dollars to flood the market with American-made contact lenses, but retirees banking on Medicare to share the cost are about to get a rude awakening at the pharmacy counter.

ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.

The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.

An 8% yield looks like a shortcut to $80,000 a year without selling a single share, but the brokerage account tells a different story than the headline number does.

Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.

Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.

LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.

Annuity payouts are the most competitive they have been in years, which makes the timing of this comparison unusually consequential for anyone sitting on a $675,000 nest egg and trying to decide which structure actually puts more money in their pocket for life.

Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04%...

Replacing a six-figure salary with dividends is a math problem first, and the capital requirement swings by more than a million dollars depending on one variable most investors treat as an afterthought.

The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.

Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.

Goldman Sachs just handed Microsoft its most coveted endorsement while cutting three other tech giants loose, and the reasoning behind that trade reveals exactly where Wall Street thinks the AI money flows next.

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph

GS, JPM, TRV and JNJ stand out as Dow hits a new high amid an AI-driven tech sell-off, with these blue-chip stocks backed by strong earnings growth.

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Medicare quietly pockets a chunk of your Social Security before it ever reaches you, and the gap between what you expect and what you receive keeps widening every year. Three ETFs target that exact shortfall with income built to arrive on a schedule.

The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.

SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.

Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of OTTAVA as its first table integrated, soft tissue robotic platform. This marks Johnson & Johnson's entry into the competitive surgical robotics market with a differentiated system design. For investors watching Johnson & Johnson, the OTTAVA approval adds a new dimension to the MedTech story. Surgical robotics has become a focus area for...

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode. After days of urging investors to accumulate the stock following a strong earnings report that Wall Street initially dismissed, Cramer highlighted the FDA approval of JNJ’s OTTAVA Robotic Surgical System as the catalyst that finally […]

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.